The HealthCare segment of
) and partner,
Onyx Pharmaceuticals Inc.
) recently announced positive results from the phase III DECISION
study on Nexavar (sorafenib) tablets in patients suffering from
locally advanced or metastatic radioactive iodine
(RAI)-refractory differentiated thyroid cancer.
Bayer mentioned in its press release that currently there are
no specific approved treatments for radioactive iodine refractory
differentiated thyroid cancer.
Results from the study revealed a significant increase in
progression-free survival (PFS) for patients treated with Nexavar
compared to placebo. Data revealed a 41% reduction in the risk of
disease progression or death for patients receiving Nexavar
compared to patients under placebo. Bayer intends to present data
from this study at the 49th Annual Meeting of the American
Society of Clinical Oncology (ASCO) in Chicago.
Hand-foot skin reaction, diarrhea, alopecia,
rash/desquamation, fatigue, weight loss and hypertension were
some of the most common treatment-emergent adverse events in the
Bayer now plans to submit marketing authorization application
for Nexavar for the treatment of RAI-refractory differentiated
thyroid cancer based on the positive findings from the phase III
We note that Nexavar is already approved as an oral
anti-cancer therapy for liver cancer and for the treatment of
patients suffering from advanced kidney cancer in over 100
countries around the globe. The drug is also approved for the
treatment of hepatocellular carcinoma and advanced renal cell
carcinoma who have failed prior interferon-alpha/interleukin-2
based therapy or are considered unsuitable for such therapy in
Bayer presently carries a Zacks Rank #3 (Hold). Meanwhile,
other stocks such as
) currently look more attractive carrying a Zacks Rank #1 (Strong
BAYER A G -ADR (BAYRY): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.